204 related articles for article (PubMed ID: 11483881)
1. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
[TBL] [Abstract][Full Text] [Related]
2. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
3. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock.
Chin A; Radhakrishnan J; Fornell L; John E
J Pediatr Surg; 2002 Mar; 37(3):482-7. PubMed ID: 11877672
[TBL] [Abstract][Full Text] [Related]
4. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
Chin A; Radhakrishnan J; Fornell L; John E
J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
[TBL] [Abstract][Full Text] [Related]
5. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction.
Clozel M; Qiu C; Qiu CS; Hess P; Clozel JP
J Am Coll Cardiol; 2002 Jan; 39(1):142-7. PubMed ID: 11755300
[TBL] [Abstract][Full Text] [Related]
6. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
[TBL] [Abstract][Full Text] [Related]
8. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function.
Yamauchi-Kohno R; Miyauchi T; Hoshino T; Kobayashi T; Aihara H; Sakai S; Yabana H; Goto K; Sugishita Y; Murata S
Circulation; 1999 Apr; 99(16):2171-6. PubMed ID: 10217659
[TBL] [Abstract][Full Text] [Related]
9. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
10. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
Konrad D; Oldner A; Rossi P; Wanecek M; Rudehill A; Weitzberg E
Crit Care Med; 2004 May; 32(5):1192-9. PubMed ID: 15190972
[TBL] [Abstract][Full Text] [Related]
11. Effects of endothelin receptors ET(A) and ET(B) blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure.
Abassi Z; Francis B; Wessale J; Ovcharenko E; Winaver J; Hoffman A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():245S-248S. PubMed ID: 12193096
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure.
Zhang PL; Mackenzie HS; Totsune K; Troy JL; Brenner BM
Circ Res; 1995 Dec; 77(6):1240-5. PubMed ID: 7586237
[TBL] [Abstract][Full Text] [Related]
13. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
[TBL] [Abstract][Full Text] [Related]
14. sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
Lundgren J; Kylhammar D; Hedelin P; Rådegran G
Acta Physiol (Oxf); 2012 Nov; 206(3):178-94. PubMed ID: 22682645
[TBL] [Abstract][Full Text] [Related]
15. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
[TBL] [Abstract][Full Text] [Related]
16. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G; Kiowski W; Kaluski E; Kobrin I; Milovanov O; Marmor A; Jafari J; Reisin L; Krakover R; Vered Z; Caspi A
Eur J Heart Fail; 2001 Aug; 3(4):457-61. PubMed ID: 11511432
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
[TBL] [Abstract][Full Text] [Related]
18. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure.
Kos T; Pacher R; Wimmer A; Bojic A; Hülsmann M; Frey B; Mayer G; Yilmaz N; Skvarilova L; Spinar J; Vitovec J; Toman J; Woloszcuk W; Stanek B
Wien Klin Wochenschr; 1998 Feb; 110(3):89-95. PubMed ID: 9553203
[TBL] [Abstract][Full Text] [Related]
19. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
Hedelin P; Kylhammar D; Rådegran G
Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
[TBL] [Abstract][Full Text] [Related]
20. Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.
Ryu SM; Kim HJ; Cho KR; Jo WM
J Korean Med Sci; 2009 Oct; 24(5):782-8. PubMed ID: 19794971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
